Literature DB >> 20868762

E3 ubiquitin ligases in ErbB receptor quantity control.

Kermit L Carraway1.   

Abstract

Signaling through ErbB family growth factor receptor tyrosine kinases is necessary for the development and homeostasis of a wide variety of tissue types. However, the intensity of receptor-mediated cellular signaling must fall within a precise range; insufficient signaling can lead to developmental abnormalities or tissue atrophy, while over-signaling can lead to hyperplastic and ultimately neoplastic events. While a plethora of mechanisms have been described that regulate downstream signaling events, it appears that cells also utilize various mechanisms to regulate their ErbB receptor levels. Such mechanisms are collectively termed "ErbB receptor quantity control." Notably, studies over the past few years have highlighted roles for post-transcriptional processes, particularly protein degradation, in ErbB quantity control. Here the involvement of ErbB-directed E3 ubiquitin ligases is discussed, including Nrdp1-mediated ErbB3 degradation, ErbB4 degradation mediated by Nedd4 family E3 ligases, and CHIP-mediated ErbB2 degradation. The hypothesis is forwarded that protein degradation-based ErbB quantity control mechanisms play central roles in suppressing receptor overexpression in normal cells, and that the loss of such mechanisms could facilitate the onset or progression of ErbB-dependent tumors.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868762      PMCID: PMC2991564          DOI: 10.1016/j.semcdb.2010.09.006

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  112 in total

Review 1.  Involvement of the neuregulins and their receptors in cardiac and neural development.

Authors:  K L Carraway
Journal:  Bioessays       Date:  1996-04       Impact factor: 4.345

2.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

Authors:  P M Guy; J V Platko; L C Cantley; R A Cerione; K L Carraway
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

3.  Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells.

Authors:  Y Murakami; S Mizuno; Y Uehara
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

4.  Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.

Authors:  G Levkowitz; L N Klapper; E Tzahar; A Freywald; M Sela; Y Yarden
Journal:  Oncogene       Date:  1996-03-07       Impact factor: 9.867

5.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Authors:  P M Siegel; D L Dankort; W R Hardy; W J Muller
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

6.  Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.

Authors:  H H Kim; S L Sierke; J G Koland
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

7.  Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.

Authors:  E G Mimnaugh; C Chavany; L Neckers
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

8.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

Authors:  P M Siegel; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

Authors:  M Alimandi; A Romano; M C Curia; R Muraro; P Fedi; S A Aaronson; P P Di Fiore; M H Kraus
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

10.  All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.

Authors:  J Baulida; M H Kraus; M Alimandi; P P Di Fiore; G Carpenter
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

View more
  26 in total

1.  EGFs and ERBBs--brief history and prospects.

Authors:  David F Stern
Journal:  Semin Cell Dev Biol       Date:  2010-10-21       Impact factor: 7.727

Review 2.  Ubiquitin-dependent sorting in endocytosis.

Authors:  Robert C Piper; Ivan Dikic; Gergely L Lukacs
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-01-01       Impact factor: 10.005

3.  Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp/c70 protein and the CHIP E3 ligase.

Authors:  Yoshihiro Matsumura; Juro Sakai; William R Skach
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

4.  The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.

Authors:  Jason Hatakeyama; Jessica H Wald; Hanine Rafidi; Antonio Cuevas; Colleen Sweeney; Kermit L Carraway
Journal:  Sci Signal       Date:  2016-06-28       Impact factor: 8.192

Review 5.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

6.  Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.

Authors:  William H D Fry; Catalina Simion; Colleen Sweeney; Kermit L Carraway
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

Review 7.  Membrane Protein Quantity Control at the Endoplasmic Reticulum.

Authors:  Ignat Printsev; Daniel Curiel; Kermit L Carraway
Journal:  J Membr Biol       Date:  2016-10-14       Impact factor: 1.843

8.  Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia.

Authors:  Jörg Neddens; Kenneth N Fish; Ludovic Tricoire; Detlef Vullhorst; Alon Shamir; Wonjae Chung; David A Lewis; Chris J McBain; Andrés Buonanno
Journal:  Biol Psychiatry       Date:  2011-06-12       Impact factor: 13.382

9.  Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Authors:  Yassamine Lazrek; Olivier Dubreuil; Véronique Garambois; Nadège Gaborit; Christel Larbouret; Christophe Le Clorennec; Gaelle Thomas; Wilhem Leconet; Marta Jarlier; Martine Pugnière; Nadia Vié; Bruno Robert; Céline Monnet; Khalil Bouayadi; Hakim Kharrat; Philippe Mondon; André Pèlegrin; Thierry Chardès
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

10.  CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.

Authors:  Shiao-Ya Hong; Yi-Ping Shih; Tianhong Li; Kermit L Carraway; Su Hao Lo
Journal:  Cancer Res       Date:  2013-06-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.